阿利西尤单抗与依洛尤单抗的疗效和安全性:随机对照试验的系统评价与荟萃分析
结果显示PCSK9抑制剂降低心肌梗死、缺血性卒中和冠状动脉血运重建风险,全因死亡和心血管死亡无统计学显著差异,安全性良好。
要点
- PCSK9抑制剂降低心肌梗死风险(RR 0.80,95%CI 0.74-0.86)。
- PCSK9抑制剂降低缺血性卒中风险(RR 0.78,95%CI 0.67-0.89)。
- 全因死亡和心血管死亡无统计学显著差异,安全性良好。
核心结论
- 阿利西尤单抗或依洛尤单抗抑制PCSK9与心肌梗死、卒中和冠状动脉血运重建风险降低相关,且安全性良好。
主要发现
- PCSK9抑制剂对全因死亡和心血管死亡的影响无统计学显著性(P=0.15和P=0.34)。
- PCSK9抑制剂降低心肌梗死风险(1.49 vs. 1.93每100患者年;RR 0.80,95%CI 0.74-0.86;I²=0%;P<0.0001)。
- PCSK9抑制剂降低缺血性卒中风险(0.44 vs. 0.58每100患者年;RR 0.78,95%CI 0.67-0.89;I²=0%;P=0.0005)。
- PCSK9抑制剂降低冠状动脉血运重建风险(2.16 vs. 2.64每100患者年;RR 0.83,95%CI 0.78-0.89;I²=0%;P<0.0001)。
- PCSK9抑制剂不增加神经认知不良事件(P=0.91)、肝酶升高(P=0.34)、横纹肌溶解(P=0.58)或新发糖尿病(P=0.97)风险。
临床怎么用
- 对于血脂异常或动脉粥样硬化性心血管疾病患者,阿利西尤单抗或依洛尤单抗可用于降低心肌梗死、卒中和冠状动脉血运重建风险。
- 使用PCSK9抑制剂时无需担忧神经认知不良事件、肝酶升高、横纹肌溶解或新发糖尿病风险增加。
局限性
- 平均加权随访时间仅2.3年,长期疗效与安全性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The effect of low-density lipoprotein cholesterol-lowering therapy with alirocumab or evolocumab on individual clinical efficacy and safety endpoints remains unclear. We aimed to evaluate the efficacy and safety of alirocumab and evolocumab in patients with dyslipidaemia or atherosclerotic cardiovascular disease. METHODS AND RESULTS: We performed a review of randomized controlled trials (RCTs) comparing treatment with alirocumab or evolocumab vs. placebo or other lipid-lowering therapies up to March 2018. Primary efficacy endpoints were all-cause death, cardiovascular death, myocardial infarction (MI), and stroke. We estimated risk ratios (RR) and 95% confidence intervals (CI) using random effect models. We included 39 RCTs comprising 66 478 patients of whom 35 896 were treated with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (14 639 with alirocumab and 21 257 with evolocumab) and 30 582 with controls. Mean weighted follow-up time across trials was 2.3 years with an exposure time of 150 617 patient-years. Overall, the effects of PCSK9 inhibition on all-cause death and cardiovascular death were not statistically significant (P = 0.15 and P = 0.34, respectively). Proprotein convertase subtilisin-kexin type 9 inhibitors were associated with lower risk of MI (1.49 vs. 1.93 per 100 patient-year; RR 0.80, 95% CI 0.74-0.86; I 2 = 0%; P < 0.0001), ischaemic stroke (0.44 vs. 0.58 per 100 patient-year; RR 0.78, 95% CI 0.67-0.89; I 2 = 0%; P = 0.0005), and coronary revascularization (2.16 vs. 2.64 per 100 patient-year; RR 0.83, 95% CI 0.78-0.89; I 2 = 0%; P < 0.0001), compared with the control group. Use of these PCSK9 inhibitors was not associated with increased risk of neurocognitive adverse events (P = 0.91), liver enzymes elevations (P = 0.34), rhabdomyolysis (P = 0.58), or new-onset diabetes mellitus (P = 0.97). CONCLUSION: Proprotein convertase subtilisin-kexin type 9 inhibition with alirocumab or evolocumab was associated with lower risk of MI, stroke, and coronary revascularization, with favourable safety profile.
引用
- Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2022. PMID: 31270529. doi:10.1093/eurheartj/ehz430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。